Anticoagulation therapy during haemodialysis: A comparative study between two heparin regimens

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 1, 2009, Pages 57-62

  Sabry, Alaa ^a   Taha, Moammer ^a   Nada, Mamdouh ^a   Al Fawzan, Fawzan ^a   Alsaran, Khalid ^a  

^a Prince Salman Center for Kidney Disease   (Saudi Arabia)

Author keywords

Anticoagulation; Haemodialysis; Lipids; Low molecular weight heparin

Indexed keywords

HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTAMINE SULFATE; TINZAPARIN; TRIACYLGLYCEROL;

ADULT; AIR TRAP CLOTTING; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL KIDNEY; BLEEDING; BLOOD CLOTTING; BOLUS INJECTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIALYZER CLOTTING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HEALTH CARE COST; HEMODIALYSIS; HUMAN; MALE; NOSE; PRESCRIPTION; PRIORITY JOURNAL; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICOAGULANTS; BLOOD COAGULATION; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEPARIN; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 58849121316     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32831bec0f     Document Type: Article

References (26)

1. Ljungberg B, Jacobson SH, Lins IE, Pejler G. Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane. Clin Nephrol 1992; 38: 97-100.
2. Pham FT, Miller JM, Demetrion G, Lew SQ. Clotting by heparin of hemoaccess for hemodialysis in an end-stage renal disease patient. Am J Kidney Dis 1995; 25: 642-647.
3. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
4. Schmitt Y, Schneider H. Low-molecular-weight heparin (LMWH): influence on blood lipids in patients on chronic haemodialysis. Nephrol Dial Transplant 1993; 8: 438-442.
5. Bratt G, Tornebohm E, Lockner D, Bergstrom K. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemost 1985; 53: 208-211.
6. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114: 489S-510S.
7. Nikolay J, Schulz E, Traut G, Nieth H, Biesel E, Zielke E. The effect of anticoagulation with low-molecular-weight heparin upon increased triglyceride and cholesterol concentrations in chronic hemodialysis patients. Nieren Hochdruckkr 1990; 19: 519-523.
8. Stenvinkel P. Low molecular weight heparin: does it favourably affect lipid levels? Nephrol Dial Transplant 1995; 10: 16-18.
9. Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Köstering H, et al. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988; 33: 890-896.
10. Deuber HJ, Schulz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991; 40: 496-500.
11. Hombrouckx R, Devos JY, Larno L. Standard heparin (SM) versus 3 low-molecular-weight heparins (LMWH) in chronic dialysis. Nephrol Dial Transplant 1994; 9: 988; [abstract].
12. Kronenberg F, König P, Lhotta K, Steinmetz A, Dieplinger H. Is low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clin Nephrol 1995; 43: 399-404.
13. Lohr JW, Schwab SJ. Minimizing hemorrhagic complications in dialysis patients. J Am Soc Nephrol 1991; 2: 961 -975.
14. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79:1 - 17.
15. Saltissi 1 D, Morgan 1 C, Westhuyzen J, Healy H. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 1999; 14: 2698-2703.
16. Siguenza F, Maduell F, Perella M, Lopez-Menchero R, Grau R, Pastor E. Low molecular weight heparin ('fragmin') in haemodialysis: is laboratory monitoring worthwhile? Nephrol Dial Transplant 1995; 10: 2163-2164.
17. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853-906.
18. Wanner C. Importance of hyperlipidaemia and therapy in renal patients. Nephrol Dial Transplant 2000; 15 (Suppl 5):92-96.
19. Oda H, Keane WF. Lipid abnormalities in end-stage renal disease. Nephrol Dial Transplant 1998; 13 (Suppl 1): 45-49.
20. Arnadottir M. Pathogenesis of dyslipoproteinemia in renal insufficiency. The role of lipoprotein lipase and hepatic lipase. Scand J Clin Lab Invest 1997; 57: 1-11.
21. Campos H, Dreon DM, Krauss RM. Associations of hepatic and lipoprotein lipase activities with changes in dietary composition and low density lipoprotein subclasses. J Lipid Res 1995; 36:462-472.
22. Arnadottir M, Kurkus J, Nilsson-Ehle P. Different types of heparin in hemodialysis: long-term effects on postheparin lipases. Scand J Clin Lab Invest 1994; 54: 515-521.
23. Spaia S, Pangidis P, Kanetidis D, et al. Longterm effects of low molecular-weight heparin in hemodialyzed patients. Hellen Nephrol 1994; 6: 426-430.
24. Kronenberg F, Konig P, Neyer U, Auinger M, Pribasnig A, Meisl T, et al. Influence of various heparin preparations on lipoproteins in hemodialysis patients: a multicenter study. Thromb Haemost 1995; 74: 1025-1028.
25. Ouseph R, Brier ME, Ward RA. Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses. Am J Kidney Dis 2000; 35: 89-94.
26. Guillet B, Simon N, Sampol JJ, Lorec-Penet AM, Portugal H, Berland Y, et al. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant 2003; 18: 2348-2353.